Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
- Rapidly transforming into a leading global biopharma company January 09, 2026…
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
November 25, 2025 18:15 ET | Source: Ascendis Pharma – Prescription Drug…
